GS
CHRS icon

George Soros’s Coherus Oncology CHRS Stock Holding History

George Soros’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-127,600
Closed -$2.93M – 243
2015
Q4 		$2.93M Hold
127,600
– – 0.05% 142
2015
Q3 		$2.56M Hold
127,600
– – 0.04% 171
2015
Q2 		$3.69M Buy
+127,600
New +$3.23M 0.03% 186

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

George Soros's CHRS Position: Q1 2016 in Review

George Soros sold out of Coherus Oncology (CHRS) in Q1 2016, closing a stake of 127,600 shares — an estimated $2.93M sold.

George Soros first reported a position in CHRS in Q2 2015 and held it in 3 quarters. The position peaked at $3.69M in Q2 2015. 75 funds tracked by Wall St. Rank hold CHRS as of Q1 2016.

  • George Soros reported no remaining Coherus Oncology position as of Q1 2016 after selling out during the quarter.
  • George Soros sold 127,600 Coherus Oncology shares in Q1 2016, an estimated $2.93M.
  • George Soros first reported a position in Coherus Oncology in Q2 2015 and held it in 3 quarters.
  • George Soros's Coherus Oncology position peaked at $3.69M in Q2 2015.
  • 75 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2016.

Based on Soros Fund Management's 13F filing for Q1 2016, filed 16 May 2016.